NPS Pharma Incurs Narrower 1Q Loss - Analyst Blog
2013年5月14日 - 6:23PM
Zacks
NPS Pharmaceuticals, Inc. (NPSP) reported first
quarter 2013 net loss per share of 9 cents per share, narrower than
the Zacks Consensus Estimate of a loss of 13 cents and the year-ago
loss of 12 cents. The narrower loss was primarily attributable to
higher revenues.
First quarter 2013 revenues climbed 11% to $25.4 million. Bulk of
the revenues ($24.8 million) in the first quarter of 2013 came from
royalties. The remaining revenues came from Gattex (teduglutide).
Revenues were below the Zacks Consensus Estimate of $28
million.
NPS Pharma launched Gattex in Feb 2013, following approval by the
US Food and Drug Administration (FDA) in Dec 2012. The drug was
cleared for treating adults with short bowel syndrome (SBS),
dependent on parenteral support. NPS Pharma stated in its press
release that as of May 3 2013, 42 SBS patients were treated with
Gattex.
Moreover, 160 Gattex prescriptions were received until that
date. The company expects peak sales of Gattex in the US to exceed
$350 million. The drug is approved in Europe (Sep 2012) under the
trade name Revestive.
In the first quarter of 2013, research and development expenses
were $15.7 million, down 22.3%. Lower clinical development expenses
and adjustments related to completion of some clinical trials led
to the decline. In the first quarter of 2013, general and
administrative expenses climbed 82.1% to $14.2 million. Costs
pertaining to the launch of Gattex in the US were responsible for
the huge increase.
NPS Pharma is also developing Natpara (rhPTH [1-84]) for the
treatment of adult hypoparathyroidism. The company expects to
submit a Biologic License Application to the FDA for the drug
during the remainder of the year.
2013 Guidance
NPS Pharma continues to expect total operating expenses, including
share-based compensation expenses for 2013 in the range $135 -$145
million.
NPS Pharma carries a Zacks Rank #3 (Hold). Companies such as
Lannett, Inc. (LCI), Cubist
Pharmaceuticals Inc. (CBST) and Celgene
Corporation (CELG) appear to be more attractive with a
Zacks Rank #2 (Buy).
CUBIST PHARM (CBST): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
NPS PHARMA INC (NPSP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Lannett CO (アメリカ証券取引所): 0 recent articles
その他のLondon Clubsニュース記事